Montelukast and DayQuil Interaction Guidelines

Medication Overview

Montelukast is a leukotriene receptor antagonist used for allergic rhinitis and asthma management, primarily dosed as 10mg once daily for adults, with a long elimination half-life supporting once-daily dosing, as recommended by the American Academy of Allergy, Asthma, and Immunology 1
DayQuil typically contains acetaminophen, dextromethorphan, and phenylephrine, with acetaminophen being a pain reliever/fever reducer, according to the American Thoracic Society 3
Dextromethorphan and phenylephrine in DayQuil are a cough suppressant and nasal decongestant, respectively, as noted by the American Academy of Allergy, Asthma, and Immunology 1

Clinical guidelines do not list contraindications or precautions for concurrent use of montelukast with DayQuil components, as stated by the American Thoracic Society and the American Academy of Allergy, Asthma, and Immunology 1, 4
The American Thoracic Society guidelines mention montelukast's safety profile without noting interactions with common cold medications, indicating a low risk of adverse interactions 3, 4
Montelukast can be used together with DayQuil for patients with allergic rhinitis and cold symptoms, providing continuous control and addressing acute symptoms, as recommended by the American Academy of Allergy, Asthma, and Immunology 1
For patients with asthma and allergic rhinitis, montelukast provides continuous control while DayQuil addresses acute cold symptoms, according to the American Thoracic Society 4

No dose adjustments of either medication are required when used concurrently in patients with normal liver and kidney function, as noted by the American Academy of Allergy, Asthma, and Immunology 2
Pediatric patients require varying dosing of montelukast based on age, with 10mg for adults, 5mg for children 6-14 years, and 4mg for children 2-5 years, as recommended by the American Academy of Pediatrics 5

The FDA has a black box warning for montelukast regarding potential neuropsychiatric events, and patients should be monitored for unusual symptoms when starting the combination, as advised by the American Thoracic Society 6